TEMPLE CITY, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ:FLGT) (“Fulgent” or the “company”) today announced financial results for its second quarter ended June 30, 2017.
Second quarter revenue was $4.6 million, an increase of 17% year over year from $4.0 million in the second quarter of 2016. GAAP loss for the second quarter of 2017 was $25,000, or $0.00 per share, and non-GAAP income, which excludes equity-based compensation expenses and equity in net loss of affiliate, and uses a corporate tax rate of 38% for the quarter, was $284,000, or $0.02 per share. Adjusted EBITDA was $685,000 in the second quarter of 2017.
